Danaher Corp
Q1 2026 Earnings
Market Reaction
S&P 500 over the same 30 days: +4.59%.
Did DHR Beat Earnings? Q1 2026 Results
Danaher posted a solid first quarter for fiscal 2026, clearing the earnings bar on the bottom line while falling just short on revenue, a combination that nonetheless left investors with a broadly reassuring picture of the company's trajectory. Adjusted diluted EPS came in at $2.06, beating the $1.94 consensus by 6.38%, while revenue of $5.95 billion grew 3.7% year over year but edged slightly below the $6.00 billion estimate by 0.77%. The headline driver behind the earnings strength was Biotechnology, where total sales climbed 11.5% and core sales rose 7.0%, fueled by continued momentum in Bioprocessing; that outperformance more than offset a soft Diagnostics segment, which contracted 4.0% on a core basis as a lighter-than-typical respiratory season weighed on Cepheid. The quarter also carried a major strategic footnote, with Danaher announcing its intent to acquire patient monitoring firm Masimo Corporation. Management lifted the upper end of full-year adjusted EPS guidance to a range of $8.35 to $8.55, while maintaining core revenue growth expectations of 3% to 6% for the full year.
- Strength in Bioprocessing drove Biotechnology segment growth of 7.0% on a core basis
- Better-than-expected Life Sciences performance
- Favorable currency exchange rates contributed 3.0% to reported sales growth
- Productivity gains and innovation acceleration
- Lighter-than-typical Q1 respiratory season at Cepheid negatively impacted Diagnostics
“Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 10% adjusted EPS growth. On the top line, we continued on a steady recovery path with strength in Bioprocessing and better-than-expected performance in Life Sciences largely offsetting the impact of a lighter-than-typical Q1 respiratory season at Cepheid.”
Danaher CEO, on the earnings call
Forward Guidance & Outlook
For Q2 2026, Danaher expects non-GAAP core revenue to increase in the low-single digit percent range year-over-year, with an adjusted operating profit margin of approximately 26.5%. For full year 2026, the company continues to expect core revenue growth of 3% to 6% and raised its adjusted diluted net EPS guidance to $8.35–$8.55 (from $8.35–$8.50). Segment-level full-year core sales growth expectations: Biotechnology approximately +6.0%, Life Sciences up slightly, and Diagnostics low-single digit growth. Cepheid respiratory revenue is expected to be approximately $1.6–$1.7 billion for the full year. The estimated effective tax rate is approximately 17.0% and the impact of currency exchange rates on sales is estimated at +0.5% for both Q2 and full year 2026.
DHR YoY Financials
DHR Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.